Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19

Inclusion Criteria: * Reside in a country where there are ongoing Lilly-sponsored clinical trials (currently this is only the United States) * Present within 10 days of symptom onset * Have severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) confirmed by reverse transcription polymerase chain reaction (RT-PCR) within the last three days * Participants greater than or equal to (≥) 65 years of age OR * Participants ≥ 12 years of age who weigh at least 40 kilograms AND have at least one of the following: * Cancer * Chronic kidney disease * Chronic obstructive pulmonary disease (COPD) or other chronic lung disease * Immunocompromised state (weakened immune system or on immunomodulatory medications) * Obesity (body mass index \[BMI\] of 35 or higher) * Serious heart conditions such as heart failure, coronary artery disease or cardiomyopathies * Sickle cell disease * Diabetes mellitus (Types 1 or 2) Exclusion Criteria: * Require hospitalization greater than (\>) 24 hours or hospice care. Residents in long term care or skilled nursing facilities that meet the inclusion criteria and are not on mechanical ventilation will be considered * Bamlanivimab should not be used in patients hospitalized with severe COVID-19 respiratory disease